CAI
resolvedCaris Life Sciences, Inc.
Price Chart
Gap Information
Score Analysis
Model 1: Rerate Score
Model 2: Trade Probability
AI Thesis
Caris Life Sciences is experiencing a significant post-earnings rerating, with a 15.5% gap on 3.21x average volume — a combination that suggests institutional repositioning rather than retail noise. As a precision medicine and molecular profiling company, Caris sits at the intersection of two powerful Wall Street themes: oncology diagnostics growth and AI-enabled drug discovery. A gap of this magnitude likely reflects a meaningful acceleration in revenue (particularly from their Caris Molecular Intelligence platform), improving margins, and/or a compelling forward guidance raise that contradicts any prior bearish narrative around cash burn or competitive pressures. The volume signature at 3.21x is especially noteworthy because it indicates broad participation — not just a short squeeze or low-float artifact. For a precision medicine company, Wall Street typically reprices when three things converge: (1) volume growth in core testing, (2) a credible path to sustained profitability or FCF positivity, and (3) pipeline/partnership catalysts that expand the addressable market. The current price of $20.94 (above the opening gap of $19.00) suggests the stock is holding its gains and potentially continuing higher intraday, which is a bullish confirmation signal for further upside.
Analyzed by rerate-v2+glm-5.2 · Aug 7, 2026
Catalysts
- Accelerating adoption of Caris Molecular Intelligence (CMI) precision oncology platform driving revenue beat
- Significant improvement in gross margins signaling operating leverage as scale builds
- Raised forward guidance implying faster-than-expected path to profitability
- AI-driven drug discovery partnerships or data collaborations with pharma companies creating new revenue streams
- Growing biopharma services revenue segment diversifying away from pure diagnostics
- Large installed base of tumor profiles creating competitive moat and data network effects
Risks
- Reimbursement pressure from Medicare/private payers for molecular profiling tests could compress margins
- Competition from larger diagnostics players (Foundation Medicine/Roche, Tempus, Guardant Health) intensifying
- Cash burn trajectory if path to FCF positivity is slower than guidance suggests
- Recent IPO with limited trading history may amplify volatility and gap risk on any disappointment
- Dependence on biopharma partnership timing creates lumpiness in revenue
- Macro-driven risk-off rotation could hit unprofitable growth-stage healthcare names disproportionately
Technical Setup
Forward Returns
Outcomes calculated Aug 11, 2026
Post-Gap Validation — 5-Day Follow-Through
Day-by-Day Price Action
| Day | Close | High | Low | Volume |
|---|---|---|---|---|
| Day 1 | $22.74 | $22.77 | $20.12 | 9.40M |
| 📍 Day 2 | $23.40 | $23.44 | $22.68 | 5.91M |
| Day 3 | $23.14 | $23.66 | $22.99 | 5.86M |
| Day 4 | Pending | |||
| Day 5 | Pending | |||
Signal Breakdown
Gap held — only 0% erased, price maintained gains
Moderate volume decline (38%)
Higher highs with peak close on day 2 — continued buying interest
Minimal drawdown (-0.6%) — price held firm
No fundamental data to evaluate beat quality
Analysis updated Aug 11, 2026